References
- Bergholz J, Xiao ZX. Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron. 2012;5(3):311–322.
- Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8(2):494–501.
- Papakonstantinou N, Ntoufa S, Tsagiopoulou M, et al. Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. Int J Cancer. 2019;144(11):2695–2706. [Internet]. [cited 2021 Jan 9]. Available from: https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1002/ijc.31999.
- Banjara S, Suraweera CD, Hinds MG, et al. The Bcl-2 family: Ancient origins, conserved structures, and divergent mechanisms. Biomolecules. 2020;10(1):128. [Internet]. MDPI AG; [cited 2020 Oct 11]. Available from:/pmc/articles/PMC7022251/?report=abstract.
- Buggins AGS, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. 2010;34(7):837–842. [Internet]. [cited 2020 Oct 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/20359747/.
- Hanada M, Delia D, Aiello A, et al. bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82(6):1820–1828.
- Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944–13949.
- Burger JA, O’Brien S. Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510–527. [Internet]. Nature Publishing Group; [cited 2020 Sep 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/29777163/.
- Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: The role of antigen stimulation. J Intern Med. 2008;264(6):549–562.
- Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22–35.
- Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+,CD40L + T cells by producing CCL22. Eur J Immunol. 2002;32(5):1403–1413. [Internet]. [cited 2020 Oct 12]. Available from: https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1002/1521-4141%28200205%2932%3A5%3C1403%3A%3AAID-IMMU1403%3E3.0.CO%3B2-Y.
- Fonte E, Vilia MG, Reverberi D, et al. Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells. Haematologica. 2017;102(11):1901–1912. [Internet]. [cited 2020 Oct 13]. Available from:/pmc/articles/PMC5664394/?report = abstract.
- Thijssen R, Slinger E, Weller K, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302–e306. [cited 2020 Oct 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/25957396/.
- Sharma S, Pavlasova G, Seda V, et al. miR-29 Modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021;137(18):2481–2494.
- Lantner F, Starlets D, Gore Y, et al. CD74 induces TAp63 expression leading to B-cell survival. Blood. 2007;110(13):4303–4311.